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Abstract
Background:  Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for multimodal
postoperative pain management. We evaluated opioid-sparing effects and rehabilitative results after
perioperative celecoxib administration for total knee arthroplasty.
Methods:  This was a prospective, randomized, observer-blind control study. Eighty patients that
underwent total knee arthroplasty were randomized into two groups of 40 each. The study group received
a single 400 mg dose of celecoxib, one hour before surgery, and 200 mg of celecoxib every 12 hours for
five days, along with patient-controlled analgesic (PCA) morphine. The control group received only PCA
morphine for postoperative pain management. Visual analog scale (VAS) pain scores, active range of
motion (ROM), total opioid use and postoperative nausea/vomiting were analyzed.
Results: Groups were comparable for age, pre-operative ROM, operation duration and intraoperative
blood loss. Resting VAS pain scores improved significantly in the celecoxib group, compared with controls,
at 48 hrs (2.13 ± 1.68 vs. 3.43 ± 1.50, p = 0.03) and 72 hrs (1.78 ± 1.66 vs. 3.17 ± 2.01, p = 0.02) after
surgery. Active ROM also increased significantly in the patients that received celecoxib, especially in the
first 72 hrs [40.8° ± 17.3° vs. 25.8° ± 11.5°, p = 0.01 (day 1); 60.7° ± 18.1° vs. 45.0° ± 17.3°, p = 0.004 (day
2); 77.7° ± 15.1° vs. 64.3° ± 16.9°, p = 0.004 (day 3)]. Opioid requirements decreased about 40% (p = 0.03)
in the celecoxib group. Although patients suffering from post-operative nausea/vomiting decreased from
43% in control group to 28% in celecoxib group, this was not significant (p = 0.57). There were no
differences in blood loss (intra- and postoperative) between the groups. Celecoxib resulted in no
significant increase in the need for blood transfusions.
Conclusion: Perioperative celecoxib significantly improved postoperative resting pain scores at 48 and
72 hrs, opioid consumption, and active ROM in the first three days after total knee arthroplasty, without
increasing the risks of bleeding.
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Background
Surgical trauma induces the synthesis of prostaglandins,
which sensitize the peripheral nociceptors [1]. Non-ster-
oidal anti-inflammatory drugs (NSAIDs) inhibit prostag-
landin synthesis in the periphery and the spinal cord,
therefore decreasing the post-operative hyperalgesic state
[2]. NSAIDs have been shown to have opioid-sparing
effects [3-6] and reduce postoperative nausea and vomit-
ing (PONV) by 30% [7]. However, the analgesic effects of
perioperative NSAIDs are still uncertain [8-10]. Some
studies suggest that perioperative NSAIDs improve post-
operative pain for ambulatory arthroscopic knee [11] or
spinal fusion surgery [12]. However, few papers have dis-
cussed the effectiveness of perioperative NSAID in pain
management after total knee arthroplasty (TKA) [13-15].
Rofecoxib has been the perioperative coxib in previous
studies. However, in September 2004, it was withdrawn
from the market due to its thromboembolic effects, partic-
ularly myocardial infarction.
Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor
and an effective analgesic for acute postoperative pain
[16]. Although pre-operative non-selective NSAID use
increases the risks of bleeding [10,17], celecoxib (1200
mg daily) has no effects on serum thromboxane or plate-
let functions [16]. Celecoxib (400 mg) also has similar
analgesic effects in comparison with conventional non-
selective NSAID [4]. To achieve less postoperative pain
and better rehabilitation after TKA surgery, especially in
the first week, prescription of oral celecoxib preemptively
for pain management of TKA patients is reasonable.
Although previous studies have evaluated the analgesic
efficacy of rofecoxib, few studies to date have evaluated
the efficacy of celecoxib for TKA. In this study, we hypoth-
esized that celecoxib provides better efficacy than the use
of patient-controlled analgesic (PCA) morphine, which is
currently the standard therapy in our institute. We aimed
to compare the difference in the pain scores at rest and
ambulation, along with range of motion (ROM), mor-
phine-sparing effects, PONV, and perioperative blood loss
between patients receiving celecoxib treatment and
patients receiving PCA morphine treatment after TKA sur-
geries.
Methods
This study was performed (from September 2006 to
March 2007) after institutional IRB approval. All TKA sur-
geries were performed by one surgeon (Ching-Chuan
Jiang). Under a randomized, prospective, observer-blind
study design, subjects were sorted by random numbers
into two groups. Inclusion criteria for this study were pri-
mary osteoarthritis and an age over sixty. Exclusion crite-
ria for this study were rheumatoid arthritis, end-stage
renal disease (complete kidney dysfunction requiring
dialysis or kidney transplantation), previous cerebral vas-
cular accident history, peptic ulcers, recent myocardial inf-
arction (within 1 year), and allergy to sulf, NSAIDs, or
morphine. The National Taiwan University Hospital and
National Institutes of Health have approved the study and
all participants will provide written informed consent.
The study group (n = 40) received 400 mg oral celecoxib
at about 1 hr prior to surgery, and 200 mg every 12 hrs,
along with PCA morphine, over the first five post-opera-
tive days. The control group (n = 40) received PCA mor-
phine over the same postoperative period.
All patients had spinal anesthesia and hemovac drain
tubes inserted for postoperative blood loss evaluation.
Patient data included gender, age, range of motion
(ROM), pain scores, blood loss and procedure duration.
Pain scores were measured using a visual analog scale
(VAS), with 0 indicating no pain and 10 indicating the
worst imaginable pain [18]. Pain scores were checked by
the same observer at rest at 6, 12, 24, 48 & 72 hrs and 7
days after TKA surgery. We encouraged patients to ambu-
late 24 hrs after TKA. Pain scores at ambulation were also
analyzed. We measured the range of motion before ambu-
lation by using a goniometer. Patients were supine on the
bed and we identified bony landmarks, including the
greater trochanter, lateral femoral condyle, and the lateral
mallelous, to facilitate goniometer placement. All ranges
of motion were measured preoperatively and postopera-
tively by the same study nurse (Lih-Ching Horng). The
CPM machine was used twice a day in all patients. PCA
morphine dose and PONV occurrence were also recorded.
All NSAIDs were discontinued at seven days after surgery.
All patients received a patient-controlled analgesia (PCA)
pump after surgery. Morphine (1 mg/mL) was given intra-
venously with increases of 2 mL and a lockout interval of
10 minutes. Additionaly, thromboembolic prophlaxis
(oral aspirin 100 mg) was given for seven postoperative
days in both groups.
Table 1: Patient demographics and surgical data. There were no significant differences between these groups.
Group Age (yr) Pre-OP ROM 
(degrees)
Pre-OP VAS Surgery Duration 
(min)
Tourniquet Duration 
(min)
Intra-operative blood 
loss (ml)
Control 70 ± 7 118 ± 17 4.7 ± 1.9 75 ± 17 45 ± 13 177 ± 54
Celecoxib 70 ± 7 116 ± 18 5.1 ± 1.7 77 ± 17 46 ± 17 181 ± 63BMC Musculoskeletal Disorders 2008, 9:77 http://www.biomedcentral.com/1471-2474/9/77
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The primary endpoint was VAS pain reduction through
perioperative celecoxib administration. Group sample
sizes of 40 and 40 can achieve 85% power in the detection
of a difference of one point on a 10-point VAS scale,
which is equivalent to the minimal clinical significant dif-
ference on the VAS scale [19], in a design with four
repeated measurements when the standard deviation is
1.8 points. Group sample sizes of 40 and 40 can achieve
91% power in the detection of a difference of one point
for a 10-point VAS scale in a design with six repeated
measurements, when the standard deviation is 1.8 points.
Secondary endpoints include ROM, morphine-sparing
effects, postoperative nausea, vomiting and blood loss.
Patient demographics were analyzed by ANOVA or Chi-
squared test. Postoperative pain scores, postoperative
ROM, morphine doses, blood loss, and PONV rates were
analyzed by Mann-Whitney test. Group differences in
pain intensity and ROM were also analyzed by repeated
measures ANOVA test. Significance was defined as p <
0.05.
Results
From Sep 2006 to March 2007, ninety-seven patients that
fulfilled inclusion criteria received elective TKA surgery by
the senior author (Ching-Chuan Jiang) at the author's
institute. Fifteen patients were excluded (four with RA,
three with ESRD, six with previous CVA, and two with a
history of peptic ulcers). Two patients suffered from epi-
gastralgia, without tarry stool, during the study and were
also excluded, leaving a total of eighty patients. They were
randomized into two groups. There were no significant
differences between them in age, preoperative ROM, pre-
operative pain scores, operation duration, and intraoper-
ative blood loss (Table 1).
VAS pain scores
The celecoxib group showed less postoperative VAS pain
at rest than the control group at 48 hrs (p = 0.03) and 72
hrs (p = 0.02) after TKA surgery (Fig 1). The celecoxib
group had reduced postoperative pain at ambulation, but
did not reach significant difference when compared with
controls (Fig 2). Repeated measures ANOVA showed that
the celecoxib group had significant VAS pain score reduc-
tion over the control group at rest (p = 0.023) but not dur-
ing ambulation (p = 0.51).
Range of motion
Celecoxib significantly improved postoperative knee
ROM, especially during the first three days (Day1: p =
0.01; Day 2: p = 0.004; Day 3: p = 0.004) (Fig 3). This
group also had increased active ROM of 12–15 degrees in
comparison with the control group. Repeated measures
ANOVA showed that the celecoxib group also had signifi-
cantly better postoperative ROM improvement than the
control group (p = 0.0009).
Morphine-sparing effects and postoperative nausea and 
vomiting
The celecoxib group had significantly less demand for
PCA morphine usage (Fig 4). PCA usage during the first
24 hours was significantly lower (15.1 ± 8.7 mg vs 19.7 ±
9.6 mg; p = 0.03). Total PCA morphine usages in the
Pain scores at ambulation Figure 2
Pain scores at ambulation. There were no differences 
between the two groups. Error bar indicates standard devia-
tion.
Pain scores at rest Figure 1
Pain scores at rest. The celecoxib group had significantly 
less pain on Days 2 and 3. *: p value < 0.05, and error bar 
indicates standard deviation.BMC Musculoskeletal Disorders 2008, 9:77 http://www.biomedcentral.com/1471-2474/9/77
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celecoxib group and controls were 17.6 ± 11.9 and 24.6 ±
14.6 mg, respectively (p = 0.03). The celecoxib group used
about 40% less morphine. Postoperative nausea and vom-
iting were at 28% and 43% in the celecoxib group and
controls, respectively. However, this did not reach statisti-
cal significance (p = 0.57).
Bleeding
There were no significant differences in intraoperative
blood loss (181 vs 177 ml), postoperative blood loss
through Hemovac drain tubes (544 vs 511 ml), and post-
operative blood transfusions (3.85 vs 3.93 units) between
the celecoxib group and controls.
Discussion
In our study, we found that perioperative administration
of celecoxib, a selective COX-2 inhibitor, reduced postop-
erative VAS pain scores at rest and decreased morphine
usage while providing better ROM rehabilitation results.
Perioperative administration of celecoxib did not increase
perioperative bleeding or blood transfusion amounts.
Coxibs are effective analgesics for post-operative pain [20-
22]. To the best of our knowledge, the literature lacks a
review of perioperative celecoxib for pain management in
TKA patients. Perioperative coxibs have been shown to
reduce postoperative pain and analgesic consumption
while enhancing patient satisfaction [6]. In 2000, Reuben
and Connelly studied perioperative use of celecoxib (200
mg) and rofecoxib (50 mg) for spinal fusion surgery [12].
They concluded that both celecoxib and rofecoxib
decrease morphine consumption, but that celecoxib's
effects are limited. In their follow-up study, preoperative
celecoxib 400 mg showed better morphine-sparing effects
than a single 200 mg preoperative dose of celecoxib [23].
Therefore, we suggest that 400 mg of celecoxib is more
optimal than 200 mg in controlling acute postoperative
pain [4,6]. In our study, although VAS scores were signifi-
cantly improved at 48 and 72 hrs at rest, and repeated
measures ANOVA test also indicated that the celecoxib
group had significantly lower pain scores at rest (p =
0.023), there was no significant difference between the
two groups in pain scores at ambulation. We also demon-
strate that perioperative celecoxib improves postoperative
ROM results. The mean knee ROM was 92 degrees in the
celecoxib group and 83.8 degrees in the control group,
seven days after surgery.
NSAIDs are known to decrease opioid consumption by
30–50% [6,7,24]. In our study, perioperative celecoxib
significantly lowered it by 40%. However, the effects of
perioperative coxibs on opioid-related side effects are still
uncertain [6]. This study also showed reduced postopera-
tive nausea and vomiting (28% vs. 43%). However, there
were no differences in PONV incidence. Further evalua-
tion, using a larger sample, is called for.
Previous studies have shown that conventional preopera-
tive non-selective NSAIDs increase bleeding risks [17,25].
Conventional non-selective NSAIDs reversibly inhibit
COX and interfere with platelet functions, while selective
PCA morphine use Figure 4
PCA morphine use. Mean PCA morphine use was signifi-
cantly lower at each measurement for the celecoxib group. *: 
p value < 0.05, and error bar indicates standard deviation.
Results for the postoperative range of motion Figure 3
Results for the postoperative range of motion. The 
celecoxib group had significantly better active ROM during 
the first 3 days. *: p value < 0.05, and error bar indicates 
standard deviation.BMC Musculoskeletal Disorders 2008, 9:77 http://www.biomedcentral.com/1471-2474/9/77
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COX-2 inhibitors have less antiplatelet effects than con-
ventional non-selective NSAIDs [26,27]. In this study,
perioperative administration of 400 mg of celecoxib had
no significant effects on blood loss, thus confirming indi-
rectly that celecoxib has little effect on serum thrombox-
ane or platelet functions [16]. The analgesic effects of
aspirin may confuse the benefits of celecoxib, even
though both groups are allowed to have aspirin in our
study, and use of aspirin does not prevent the throm-
boembolic adverse effects of coxibs.
Selective COX-2 inhibitors may be a better choice for mul-
timodal analgesia than conventional non-selective
NSAID. Selective COX-2 inhibitors may have better gas-
trointestinal tolerance and less risk for cardiovascular
events. It's suggested that selective COX-2 inhibitors have
less gastrointestinal toxicity than conventional non-selec-
tive NSAIDs [28,29]. It's suggested that selective COX-2
inhibitors increase the risks of cardiovascular events, myo-
cardial infarction, stroke and heart failure [29,30], too.
White et al. also demonstrated no significant increase in
CV risks with celecoxib in comparison to placebo or non-
selective NSAIDs [31]. Moore et al. even demonstrated
that celecoxib had less gastrointestinal and cardiovascular
risk than conventional non-selective NSAIDs and all other
coxibs [32]. However, there might not be any difference in
the coxibs and conventional non-selective NSAIDs with
respect to serious vascular events [33]. Selective COX-2
inhibitors may cause less bleeding than non-selective
NSAID, because coxibs do not interfere the normal mech-
anisms of platelet aggregation and hemostasis, whereas
non-selective NSAID produces significant reductions in
platelet aggregation and serum thromboxane B2 [34]. It
has been shown that prior exposure of non-selective
NSAID such as ibuprofen in THR surgery significant
increases bleeding [10]. Therefore, we suggest that selec-
tive COX-2 is optimal for multimodal analgesia.
One limitation of this study is the lack of a true placebo
group. Placebo response has been observed in up to 30%
of patients that undergo surgery. However, placebo usage
may present ethical concerns in the postoperative care of
TKA surgery; we therefore adopted an active-control trial
design that compared celebrex treatment to the standard
therapy (PCA morphine) at our institute. Another limita-
tion was the limited research period. We recorded data for
only the first seven days. Although we demonstrated that
celecoxib had better rehabilitative results in the first week
than PCA morphine, long-term efficacy is still in question.
There may be many reasons for the resting VAS scores to
not have reached significance until 48 hours after surgery.
One possibility is that the true difference does exist and
that a larger sample size is needed to draw out the differ-
ence, despite that we had shown that the sample size in
our study had adequate power.
Conclusion
Perioperative celecoxib, combined with opioids, is an
effective and safe regimen for pain control in TKA
patients. Perioperative celecoxib can significantly decrease
postoperative pain scores at rest and opioid use, while
improving postoperative ROM results for TKA surgeries.
Considering the benefits, we suggest celecoxib for multi-
modal analgesia.
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